Category: 3. Business

1. All information offered on Porsche Newsroom, including but not limited to, texts, images, audio and video documents, are subject to copyright or other legislation for the protection of intellectual property. They are intended exclusively for use by journalists as a source for their own media reporting and are not intended for commercial use, in particular for advertising purposes. It is not permitted to pass on texts, images, audio or video data to unauthorised third parties.

2. All logos and trademarks mentioned on Porsche Newsroom are trademarks of Dr. Ing. h.c. F. Porsche AG (hereinafter: Porsche AG), unless otherwise stated.

3. All contents of Porsche Newsroom are carefully researched and compiled. Nevertheless, the information may contain errors or inaccuracies. Porsche AG does not accept any liability with respect to the results that may be achived through the use of the information, in particular with respect to accuracy, up-to-dateness and completeness.

4. Insofar as Porsche Newsroom provides information concerning vehicles, the data refers to the German market. Statements concerning standard equipment and statutory, legal and tax regulations and repercussion are valid for the Federal Public of Germany only.

5. With respect to the use of Porsche Newsroom, technical faults such as, delays to news transmission, cannot be ruled out. Porsche AG does not accept any liability for any resulting damage.

6. Insofar as Porsche Newsroom provides links to the internet sites of third parties, Porsche AG does not accept any responsibility for the content of the linked sites. On using the links, the user leaves the Porsche AG information products.

7. In agreeing to these rights of use, the user shall be obliged to refrain from any improper use of Porsche Newsroom.

8. In the event of improper use, Porsche AG reserves the right to block access to Porsche Newsroom.

9. Should one or more provisions of these terms and conditions be or become invalid, this shall not affect the validity of the remaining provisions.

Specialty

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

Ad hoc announcement pursuant to Art. 53 LR

• Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies
  
  
• One-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatment
  
• Gene replacement therapy now available to eligible people of all ages living with SMA

Basel, November 24, 2025 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma^® (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens and adults living with spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene, making it the first and only gene replacement therapy available for this broad population. Itvisma is uniquely designed to address the genetic root cause of SMA with a one-time fixed dose that does not need to be adjusted for age or body weight.¹ By replacing the SMN1 gene, Itvisma can improve motor function, offering the potential to reduce the need for chronically administered treatment associated with other available therapies for this population.¹
  
“The FDA’s approval of intrathecal onasemnogene abeparvovec is a game-changing advance, expanding the use of transformational gene replacement therapy for SMA across age groups,” said John W. Day, MD, PhD, Professor of Neurology and Pediatrics, Director, Division of Neuromuscular Medicine at Stanford University School of Medicine, and Co-Director of Stanford’s Neuro IGNITE Center. “This achievement is not only a significant step forward for SMA – it also signals new possibilities for the broader field of neurological disorders and genetic medicine.”
  
The approval of Itvisma is based on data from the registrational Phase lll STEER study and supported by the open-label Phase lllb STRENGTH study. Itvisma showed statistically significant improvements in motor function and stabilization of motor abilities typically not seen in the natural history of the disease, with effects sustained over 52 weeks of follow-up.^2,3 Additionally, Itvisma demonstrated a safety profile with adverse events that were consistent across both studies.^2,3 The most common adverse events in the STEER study were upper respiratory tract infection and pyrexia, and the most common adverse events in the STRENGTH study were common cold, pyrexia, and vomiting.^2,3 These data were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
   
“This new route of administration for a single dose of gene replacement therapy can mean so much more than what is measured by numbers on a functional motor scale – it could mean greater independence and freedom in activities of daily life,” said Kenneth Hobby, President, Cure SMA. “The SMA disease landscape has dramatically changed over the last six years, when the first gene therapy was approved. This is another welcome advancement, and it represents real progress in expanding access for many older patients and addressing the unmet needs that remain in our community.”
   
SMA is a rare, genetic neuromuscular disease caused by a mutated or missing SMN1 gene.^4,5 The SMN1 gene is responsible for producing most of the SMN protein a body needs for muscle function, including breathing, swallowing and basic movement.⁵ Without it, motor neurons are irreversibly lost, leading to progressive, debilitating muscle weakness.⁵ A second gene, the SMN2 gene, produces a small fraction (~10%) of functional SMN protein compared with the SMN1 gene.⁶ Individuals with more copies of the SMN2 gene generally have a less severe form of SMA than those with fewer copies.⁶ 
   
Approximately 9,000 people in the US live with SMA, and though there have been advancements in treating the disease, unmet needs remain for older children, teens, and adults in preserving motor neurons and maintaining physical strength.^7,8
   
Transforming care in SMA
“After redefining SMA care with the first gene replacement therapy for this challenging disease, we can now help address unmet needs across an even broader SMA population with the approval of Itvisma,” said Victor Bultó, President, Novartis, US. “We are proud to support the SMA community by empowering patients of all ages through our innovative, one-time therapies, offering the potential to reduce the burden that comes with chronic treatment.”
   
Itvisma will be available in the US in December. Novartis Patient Support is available to help eligible patients get started on treatment. Patients and providers can call 1-855-441-4363 for personalized assistance, including help understanding insurance coverage and identifying potential financial assistance options.
   
About Itvisma^® (onasemnogene abeparvovec-brve)
Itvisma is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN1 gene to improve motor function through sustained SMN protein expression with a single, one-time intrathecal injection.
   
Novartis has an exclusive, worldwide license with Nationwide Children’s Hospital to both the intravenous and intrathecal delivery of adeno-associated virus 9 (AAV9) gene replacement therapy for the treatment of all types of SMA; an exclusive, worldwide license from REGENXBIO for any recombinant AAV vector in its intellectual property portfolio for the in vivo gene replacement therapy treatment of SMA in humans; an exclusive, worldwide licensing agreement with Généthon for in vivo delivery of AAV9 vector into the central nervous system for the treatment of SMA. 
   
Novartis in neuroscience
Neurological diseases are deeply personal, affecting people of any age, from newborns to seniors, often striking in the prime of life. At Novartis, we’re doubling down on our commitment to neurology, expanding our legacy of innovation in spinal muscular atrophy (SMA) and multiple sclerosis (MS) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases. Our goal is to protect people’s health across their lifespan, developing more treatment options that lead to better outcomes.
   
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “believe,” “committed,” “commitment,” “pipeline,” “launch,” “potentially,” “step forward,” “goal,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Itvisma, or regarding potential future revenues from Itvisma. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Itvisma will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Itvisma will be commercially successful in the future. In particular, our expectations regarding Itvisma could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
   
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
   
Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
   
   
References

1. Itvisma^® (onasemnogene abeparvovec-brve). Prescribing Information. Novartis Gene Therapies, Inc.
2. Proud C, et al. Neuromuscul Disord. 2025;(53):0960-8966. 
3. Clinicaltrials.Gov. STRENGTH Study Results. https://clinicaltrials.gov/study/NCT05386680. Accessed November 2025. 
4. Anderton RS and Mastaglia FL. Expert Rev Neurother. 2015;15(8):895–908.  
5. National Organization for Rare Disorders (NORD). Spinal Muscular Atrophy. https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. Accessed November 2025.
6. Lorson CL, et al. Hum Mol Genet. 2010;(15):111-8. 
7. Cure SMA. State of SMA 2024 Report. https://www.curesma.org/wp-content/uploads/2025/04/State-of-SMA-Report2024_vWeb-4.pdf. Accessed November 2025.
8. Cure SMA. Address the Unmet Needs of Children and Adults with Spinal Muscular Atrophy. https://www.curesma.org/wp-content/uploads/2024/08/NIH_SMA_Research_FactSheet.pdf. Accessed November 2025.

# # #
   

Story Continues

LAVAL, QC, Nov. 24, 2025 /PRNewswire/ – Alimentation Couche-Tard Inc. (“Couche-Tard” or the “Corporation”) (TSX: ATD) announces its results for its second quarter ended October 12, 2025.

Executive Comments on the Quarter

Alex Miller, President and Chief Executive Officer, said: “With same-store sales^1,2 growth across all our geographies for the second consecutive quarter, along with strong margins and sequential volume growth in fuel, we are encouraged by the positive momentum we’re continuing to build in our business.  We are outperforming our industry with an offer that is clearly resonating with our customers — from the continued growth of our Meal Deals and exclusive vendor partnerships to the success of our seasonal Fuel Day events, which are driving traffic and excitement at our sites. Looking ahead, we remain focused on delivering compelling value and investing in programs that drive operational excellence, optimize our supply chain, and enhance the customer experience in the store, at the pump, and digitally. I’m proud of our team’s performance and the progress we’re making together to win our customers.”

Filipe Da Silva, Chief Financial Officer, added: “We closed the second quarter with growing optimism, reflecting steady progress supported by consistent execution and effective cost management across our operations. Core operating expenses growth remained under control, while we continued to advance our multi-year investment journey to unlock new capabilities that strengthen our network and create greater value for customers. This also marked the first full quarter from GetGo, which further broadens our food and convenience offering in the U.S. and opens new opportunities for customer engagement. During the second quarter, we also repurchased nearly $900 million of our shares through the buyback program, while, for the first half of the year, we invested close to $900 million in capital expenditures, reinforcing our balanced approach to capital allocation. As we look ahead, we remain committed to delivering earnings growth over the course of the year.”

Quarterly Highlights

• Net earnings attributable to shareholders of the Corporation were $740.6 million for the second quarter of fiscal 2026 compared with $708.8 million for the second quarter of fiscal 2025. Adjusted net earnings attributable to shareholders of the Corporation¹ were approximately $734.0 million compared with $705.0 million for the corresponding quarter of last year, representing an increase of 4.1%.
• Net earnings attributable to shareholders of the Corporation were $0.79 per diluted share for the second quarter of fiscal 2026 compared with $0.75 per diluted share for the second quarter of fiscal 2025. Adjusted diluted net earnings per share¹ were $0.78, representing an increase of 5.4% from $0.74 for the corresponding quarter of last year.
• Total merchandise and service revenues of $4.7 billion, an increase of 6.6%. Same-store merchandise revenues² increased by 1.2% in the United States, by 0.5% in Europe and other regions¹, and by 5.4% in Canada.
• Merchandise and service gross margin¹ increased by 0.9% in the United States to 34.7%, by 0.7% in Europe and other regions to 38.9%, and by 0.6% in Canada to 34.2%.
• Same-store road transportation fuel volumes decreased by 0.6% in the United States, and by 1.8% in Europe and other regions, while it increased by 1.1% in Canada.
• Road transportation fuel gross margin¹ of 45.86¢ per gallon in the United States, a decrease of 0.24¢ per gallon, US 11.51¢ per liter in Europe and other regions, an increase of US 1.00¢ per liter, and CA 15.07¢ per liter in Canada, an increase of CA 1.72¢ per liter.
• Successful issuance of US-dollar-denominated senior unsecured notes of $1.2 billion and Canadian-dollar-denominated senior unsecured notes of CA $500.0 million ($359.9 million).

Summary of the Second Quarter of Fiscal 2026

For its second quarter ended October 12, 2025, Couche-Tard reported net earnings attributable to shareholders of the Corporation of $740.6 million, representing $0.79 per share on a diluted basis, compared with $708.8 million for the corresponding quarter of fiscal 2025, representing $0.75 per share on a diluted basis. The results for the second quarter of fiscal 2026 were affected by a pre-tax net foreign exchange gain of $8.9 million and by pre-tax acquisition costs of $0.3 million. The results for the comparable quarter of fiscal 2025 were affected by a pre-tax net foreign exchange gain of $9.0 million and by pre-tax acquisition costs of $2.9 million. Excluding these items, the adjusted net earnings attributable to shareholders of the Corporation³ were approximately $734.0 million, or $0.78 per share on a diluted basis for the second quarter of fiscal 2026, compared with $705.0 million, or $0.74 per share on a diluted basis for the corresponding quarter of fiscal 2025, an increase of 5.4% in the adjusted diluted net earnings per share¹. This increase is primarily driven by the contribution from acquisitions, improved gross margins in our convenience and road transportation fuel activities and positive organic growth in our convenience activities across all our geographies, partly offset by the impact of inflation and strategic investments on our operating expenses and depreciation. All financial information presented is in US dollars unless stated otherwise.

Significant Items of the Second Quarter of Fiscal 2026

• On September 26, 2025, we issued Canadian-dollar-denominated senior unsecured notes totaling CA $500.0 million ($359.9 million) with a coupon rate of 3.86% and maturing in 2032.

  On September 29, 2025, we also issued US-dollar-denominated senior unsecured notes totaling $1.2 billion, consisting of a $700.0 million tranche with a coupon rate of 4.15% and maturing in 2028, as well as a $500.0 million tranche with a coupon rate of 5.08% and maturing in 2035.

  The $1.6 billion net proceeds from the issuance were used to repay indebtedness under our United States commercial paper program.

• On July 21, 2025, the Toronto Stock Exchange approved the renewal of our share repurchase program, which took effect on July 23, 2025. The renewed share repurchase program allows us to repurchase up to 77.1 million shares, representing 10% of our public float outstanding as at July 14, 2025, and the share repurchase period will end no later than July 22, 2026. During the second quarter and first half-year of fiscal 2026, we repurchased 16.6 million shares for an amount of $886.7 million, which includes associated taxes of $17.4 million. Subsequent to the end of the quarter, 6.1 million shares were repurchased for an amount net of taxes paid of $306.3 million.

Changes in our Network during the Second Quarter of Fiscal 2026

• We acquired 14 company-operated stores, including 7 company-owned and operated convenience retail and fuel sites operating under the Texaco brand and located in Ireland and 7 company-operated stores located in the United States. We settled these transactions using our available cash.
• During the quarter, we completed the construction of 19 stores and the relocation or reconstruction of 3 stores, reaching a total of 35 stores since the beginning of fiscal 2026. As of October 12, 2025, another 73 stores were under construction and should open in the upcoming quarters.

Summary of changes in our store network

The following table presents certain information regarding changes in our store network over the 12-week period ended October 12, 2025⁽¹⁾:

Exchange Rate Data

We use the US dollar as our reporting currency, which provides more relevant information given the predominance of our operations in the United States.

The following table sets forth information about exchange rates based upon closing rates expressed as US dollars per comparative currency unit:

For the analysis of consolidated results, the impact of the translation of our foreign currency operations into US dollars is defined as the impact from the translation of our Canadian, European, Asian, and corporate operations into US dollars. Variances of our foreign currency operations into US dollars are determined as being the difference between the corresponding period results in local currencies translated at the current period average exchange rate and the corresponding period results in local currencies translated at the corresponding period average exchange rate.

Summary Analysis of Consolidated Results for the Second Quarter and First Half-year of Fiscal 2026

The following table highlights certain information regarding our operations for the 12 and 24‑week periods ended October 12, 2025 and October 13, 2024, and the results analysis in this section should be read in conjunction with this table. The results from our operations in Europe and Asia are presented together as Europe and other regions.

Revenues

Our revenues were $17.9 billion for the second quarter of fiscal 2026, up by $460.8 million, an increase of 2.6% compared with the corresponding quarter of fiscal 2025, mainly attributable to the contribution from acquisitions and the net impact from organic changes to our network, partly offset by a lower average road transportation fuel selling price, lower revenues in our wholesale fuel business and the impact of regulatory divestiture related to the GetGo acquisition. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $332.0 million on our revenues for the second quarter.

For the first half-year of fiscal 2026, our revenues decreased by $469.8 million, or 1.3%, compared with fiscal 2025, mainly attributable to a lower average road transportation fuel selling price, softness in fuel demand and traffic in the United States and the impact of regulatory divestiture related to the GetGo acquisition, partly offset by the contribution from acquisitions as well as the net impact from organic changes to our network. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $680.0 million on our revenues.

Merchandise and service revenues

Total merchandise and service revenues for the second quarter of fiscal 2026 were $4.7 billion, an increase of $289.8 million compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $36.0 million. The remaining increase of approximately $254.0 million, or 5.8%, is primarily attributable to the contribution from acquisitions, which amounted to approximately $163.0 million and organic growth, partly offset by the impact of regulatory divestiture related to the GetGo acquisition which amounted to approximately $20.0 million. Same-store merchandise revenues increased by 1.2% in the United States, driven by successful promotions, more specifically with our Meal Deals offers, as well as within the other nicotine products category. In Canada, same-store merchandise revenues increased by 5.4%, driven by the growth in the alcohol category, while in Europe and other regions¹, it increased by 0.5%. The growing success of our food service program, as well as the expansion of the packaged beverages category contributed to the growth of all regions but were partly offset by the challenges of the cigarette industry as well as by the competition in the other nicotine products category. Changes in regulations in some geographies also continue to impact our results.

For the first half-year of fiscal 2026, the growth in merchandise and service revenues was $490.5 million, or 5.5%, compared with fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $80.0 million. Same-store merchandise revenues increased in all regions, by 0.8% in the United States, by 2.1% in Europe and other regions[4] and by 4.8% in Canada.

Road transportation fuel revenues

Total road transportation fuel revenues for the second quarter of fiscal 2026 were $13.0 billion, an increase of $165.7 million compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $289.0 million. The remaining decrease of approximately $123.0 million, or 1.0%, is mainly attributable to a lower average road transportation fuel selling price, which had a negative impact of approximately $498.0 million, softness in fuel demand, lower revenues in our wholesale fuel business and the impact of regulatory divestiture related to the GetGo acquisition, which amounted to approximately $44.0 million, partly offset by the contribution from acquisitions, which amounted to approximately $471.0 million. Same-store road transportation fuel volumes decreased by 0.6% in the United States and by 1.8% in  Europe and other regions, both driven by lower demand, while it increased by 1.1% in Canada, favorably impacted by good execution and market growth.

For the first half-year of fiscal 2026, the road transportation fuel revenues decreased by $955.9 million, or 3.6% compared with fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $587.0 million. Same-store road transportation fuel volumes decreased by 0.8% in the United States, by 1.5% in Europe and other regions, and increased by 1.7% in Canada.

The following table shows the average selling price of road transportation fuel of our company-operated stores in our various markets for the last eight quarters. The average selling price of road transportation fuel consists of the road transportation fuel revenues divided by the volume of road transportation fuel sold:

Other revenues

Total other revenues for the second quarter of fiscal 2026 were $140.0 million, an increase of $5.3 million compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $7.0 million.

For the first half-year of fiscal 2026, total other revenues were $258.1 million, a decrease of $4.4 million compared with fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $15.0 million. The remaining decrease of $19.0 million, or 7.2%, is primarily driven by lower prices on our other fuel products.

Gross profit⁵

Our gross profit was $3.4 billion for the second quarter of fiscal 2026, up by $255.8 million, or 8.1%, compared with the corresponding quarter of fiscal 2025, mainly attributable to the contribution from acquisitions, improved merchandise and service and road transportation fuel gross margin¹, as well as organic growth, partly offset by the impact of regulatory divestiture related to the GetGo acquisition. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $41.0 million.

For the first half-year of fiscal 2026, our gross profit increased by $396.7 million, or 6.3%, compared with the first half-year of fiscal 2025, mainly attributable to similar factors as those of the second quarter. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $86.0 million.

Merchandise and service gross profit

In the second quarter of fiscal 2026, our merchandise and service gross profit was $1.7 billion, an increase of $140.2 million compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $14.0 million. The remaining increase of approximately $126.0 million, or 8.3%, is mainly driven by the contribution from acquisitions, which amounted to approximately $56.0 million, by organic growth, as well as by improved merchandise and service gross margin¹ in the United States, partly offset by the impact of regulatory divestiture related to the GetGo acquisition which amounted to approximately $7.0 million. Our merchandise and service gross margin¹ increased by 0.9% in the United States to 34.7%, favorably impacted by the Zyntember promotion, as well as by strong food execution. In Europe and other regions our merchandise and service gross margin¹ increased by 0.7% to 38.9%, mostly driven by a favorable product mix from lower tobacco revenues and E-Mobility continued momentum in Scandinavia. In Canada, our merchandise and service gross margin¹ increased by 0.6% to 34.2%, driven by a favorable change in product mix from lower cigarette revenues.

During the first half-year of fiscal 2026, our merchandise and service gross profit was $3.3 billion, an increase of $227.5 million compared with the first half-year of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $33.0 million. Our merchandise and service gross margin¹ increased by 0.9% to 34.7% in the United States, decreased by 0.1% in Europe and other regions to 38.9%, and by 0.2% in Canada to 34.0%.

Road transportation fuel gross profit

In the second quarter of fiscal 2026, our road transportation fuel gross profit was $1.7 billion, an increase of $106.6 million compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $24.0 million. The remaining increase of approximately $83.0 million, or 5.2%, is mainly driven by the contribution from acquisitions, which amounted to approximately $79.0 million, as well as by improved road transportation fuel gross margin¹ in Europe and other regions and Canada, partly offset by lower road transportation fuel gross margin¹ in the United States, as well as by softness in fuel demand and traffic in both the United States and Europe and other regions, and by the impact of regulatory divestiture related to the GetGo acquisition which amounted to approximately $7.0 million. In the United States, our road transportation fuel gross margin¹ was 45.86¢ per gallon, a decrease of 0.24¢ per gallon, and in Canada, it was CA 15.07¢ per liter, an increase of CA 1.72¢ per liter. Fuel margins remained healthy throughout our network, due to the continued work on the optimization of our supply chain and strong execution in our stores. In Europe and other regions, our road transportation fuel gross profit was US 11.51¢ per liter, an increase of US 1.00¢ per liter, driven by favorable foreign exchange translation and strong supply execution, partly offset by the retroactive impact from the renegotiation of a fuel supply agreement  which had a favorable impact on prior year road transportation fuel gross margin¹.

During the first half-year of fiscal 2026, our road transportation fuel gross profit was $3.3 billion, an increase of $154.8 million compared with the first half-year of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $48.0 million. The road transportation fuel gross margin¹ was 44.95¢ per gallon in the United States, US 11.46¢ per liter in Europe and other regions, and CA 14.64¢ per liter in Canada.

The road transportation fuel gross margin¹ of our company-operated stores in the United States and the impact of expenses related to electronic payment modes for the last eight quarters, were as follows:

The road transportation fuel gross margin¹ of our network in Europe and other regions and in Canada for the last eight quarters, were as follows:

Generally, road transportation fuel gross margins⁶ can be volatile from one quarter to another but tend to be more stable over longer periods. In Europe and other regions, fuel margin volatility is impacted by a longer supply chain due to a more integrated model. In Europe and other regions and in Canada, expenses related to electronic payment modes are not as volatile as in the United States.

Other revenues gross profit

In the second quarter of fiscal 2026, other revenues gross profit was $56.3 million, an increase of $9.0 million, or 19.0%, compared with the corresponding quarter of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $2.0 million.

During the first half-year of fiscal 2026, other revenues gross profit was $110.9 million, an increase of $14.4 million, or 14.9%, compared with fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $5.0 million.

Operating, selling, general and administrative expenses (“expenses”)

For the second quarter and first half-year of fiscal 2026, expenses increased by 8.3% and 6.5%, respectively, compared with the corresponding periods of fiscal 2025. Normalized growth of expenses⁷ was 3.4% and 2.9%, respectively, as shown in the table below:

Normalized growth of expenses¹ for the second quarter of fiscal 2026 was mainly driven by inflationary pressures, incremental investments to support our strategic initiatives, as well as investments to support the acceleration of our food service program, partly offset by the continued strategic efforts to control our expenses.

For the first half-year of fiscal 2026, our disciplined approach over expenses remained evidenced by our normalized growth of expenses¹, which is in line with inflation level in our network.

Earnings before interest, taxes, depreciation, amortization and impairment (“EBITDA¹“) and adjusted EBITDA¹

During the second quarter of fiscal 2026, EBITDA stood at $1.6 billion, an increase of $116.8 million, or 7.7%, compared with the corresponding quarter of fiscal 2025. Adjusted EBITDA for the second quarter of fiscal 2026 increased by $114.2 million, or 7.5%, compared with the corresponding quarter of fiscal 2025, mainly due to the contribution from acquisitions, which amounted to approximately $65.0 million, improved merchandise and service and road transportation fuel gross margin¹, as well as organic growth in our convenience activities, partly offset by the impact of regulatory divestiture related to the GetGo acquisition which amounted to approximately $8.0 million. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $21.0 million.

During the first half-year of fiscal 2026, EBITDA stood at $3.3 billion, an increase of $199.7 million, or 6.4%, compared with the first half-year of fiscal 2025. Adjusted EBITDA for the first half-year of fiscal 2026 increased by $139.6 million, or 4.5%, compared with the first half-year of fiscal 2025, is mainly attributable to similar factors as those of the second quarter. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $42.0 million.

Depreciation, amortization and impairment (“depreciation”)

For the second quarter of fiscal 2026, our depreciation expense increased by $66.6 million, or 14.2%, compared with the second quarter of fiscal 2025, mainly driven by the replacement of equipment, the ongoing improvement of our network, strategic investments, as well as the impact from investments made through business acquisitions, which amounted to approximately $23.0 million. The translation of our foreign currency operations into US dollars had a net unfavorable impact of approximately $8.0 million on depreciation.

For the first half-year of fiscal 2026, our depreciation expense increased by $153.5 million, compared with the first half-year of fiscal 2025. The translation of our foreign currency operations into US dollars had a net unfavorable impact of approximately $16.0 million. The remaining increase of $138.0 million, or 15.2%, is mainly attributable to similar factors as those of the second quarter.

Net financial expenses

Net financial expenses for the second quarter and first half-year of fiscal 2026 were $135.4 million and $253.7 million, respectively, an increase of $17.6 million and $20.8 million, respectively, compared with the corresponding periods of fiscal 2025. A portion of the variation is explained by certain items that are not considered indicative of future trends, as shown in the table below:

The remaining variation of the second quarter and first half-year of fiscal 2026 is partly driven by higher average short-term and long-term debt in connection with our recent acquisitions.

Income taxes

The income tax rate for the second quarter was 22.8% compared with 23.4% for the corresponding quarter of fiscal 2025. The decrease is mainly stemming from the impact of a different mix in our earnings across the various jurisdictions in which we operate.

The income tax rate for the first half-year of fiscal 2026 was 23.0% compared with 23.3% for fiscal 2025. The difference is mainly attributable to similar factors as those of the second quarter.

Net earnings attributable to shareholders of the Corporation and adjusted net earnings attributable to shareholders of the Corporation⁸

Net earnings attributable to shareholders of the Corporation for the second quarter of fiscal 2026 were $740.6 million, compared with $708.8 million for the second quarter of fiscal 2025, an increase of $31.8 million, or 4.5%. Diluted net earnings per share stood at $0.79, compared with $0.75 for the corresponding quarter of the previous fiscal year. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $12.0 million on net earnings attributable to shareholders of the Corporation for the second quarter of fiscal 2026.

Adjusted net earnings attributable to shareholders of the Corporation for the second quarter of fiscal 2026 were approximately $734.0 million, compared with $705.0 million for the second quarter of fiscal 2025, an increase of $29.0 million, or 4.1%. Adjusted diluted net earnings per share¹ were $0.78 for the second quarter of fiscal 2026, compared with $0.74 for the corresponding quarter of fiscal 2025, an increase of 5.4%.

For the first half-year of fiscal 2026, net earnings attributable to shareholders of the Corporation stood at $1.5 billion, an increase of $23.5 million, or 1.6%, compared with the first half-year of fiscal 2025. Diluted net earnings per share stood at $1.61, compared with $1.57 for the corresponding period of fiscal 2025. The translation of our foreign currency operations into US dollars had a net positive impact of approximately $27.0 million on net earnings attributable to shareholders of the Corporation for the first half-year of fiscal 2026.

Adjusted net earnings attributable to shareholders of the Corporation for the first half-year of fiscal 2026 stood at $1.5 billion, a decrease of $24.0 million, or 1.6%, compared with the first half-year of fiscal 2025. Adjusted diluted net earnings per share¹ were $1.56 for the first half-year of fiscal 2026, compared with $1.57 for the first half-year of fiscal 2025, a decrease of 0.6%.

Dividends

During its November 24, 2025 meeting, the Board of Directors approved an increase in the quarterly dividend of CA 2.0¢ per share, bringing it to CA 21.5¢ per share, an increase of 10.3%.

During the same meeting, the Board of Directors declared a quarterly dividend of CA 21.5¢ per share for the second quarter of fiscal 2026 to shareholders on record as at December 3, 2025, and approved its payment effective December 17, 2025. This is an eligible dividend within the meaning of the Income Tax Act (Canada).

Non-IFRS Accounting Standards Measures

To provide more information for evaluating the Corporation’s performance, the financial information included in our financial documents contains certain data that are not performance measures under IFRS^® Accounting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”), which are also calculated on an adjusted basis to exclude specific items. Those performance measures are called “Non-IFRS Accounting Standards measures”. We believe that providing those Non-IFRS Accounting Standards measures is useful to management, investors, and analysts, as they provide additional information to measure the performance and financial position of the Corporation.

The following Non-IFRS Accounting Standards financial measures are used in our financial disclosures:

• Gross profit;
• Earnings before interest, taxes, depreciation, amortization and impairment (“EBITDA”) and adjusted EBITDA;
• Adjusted net earnings attributable to shareholders of the Corporation;
• Interest-bearing debt.

The following Non-IFRS Accounting Standards ratios are used in our financial disclosures:

• Merchandise and service gross margin and Road transportation fuel gross margin;
• Normalized growth of operating, selling, general and administrative expenses;
• Growth of (decrease in) same-store merchandise revenues for Europe and other regions;
• Adjusted diluted net earnings per share;
• Leverage ratio;
• Return on equity and return on capital employed.

The following capital management measure is used in our financial disclosures:

• Net interest-bearing debt/total capitalization.

Supplementary financial measures are also used in our financial disclosures and those measures are described where they are presented.

Non-IFRS Accounting Standards financial measures and ratios, as well as the capital management measure, are mainly derived from the consolidated financial statements but do not have standardized meanings prescribed by IFRS Accounting Standards. These Non-IFRS Accounting Standards measures should not be considered in isolation or as a substitute for financial measures prepared in accordance with IFRS Accounting Standards. In addition, our definitions of Non-IFRS Accounting Standards measures may differ from those of other public corporations. Any such modification or reformulation may be significant. These measures may also be adjusted for the pro forma impact of our acquisitions and impacts of new accounting standards if they are considered to be material.

Gross profit. Gross profit consists of Revenues less the Cost of sales, excluding depreciation, amortization and impairment. This measure is considered useful for evaluating the underlying performance of our operations.

The table below reconciles Revenues and Cost of sales, excluding depreciation, amortization and impairment, as per IFRS Accounting Standards, to Gross profit:

Please note that the same reconciliation applies in the determination of gross profit by category and by geography presented in the section “Summary Analysis of Consolidated Results”.

Merchandise and service gross margin. Merchandise and service gross margin consists of Merchandise and service gross profit divided by Merchandise and service revenues, both measures are presented in the section “Summary Analysis of Consolidated Results”. Merchandise and service gross margin is considered useful for evaluating how efficiently we generate gross profit by dollar of revenue.

Road transportation fuel gross margin. Road transportation fuel gross margin consists of Road transportation fuel gross profit divided by Total volume of road transportation fuel sold. For the United States and Europe and other regions, both measures are presented in the section “Summary Analysis of Consolidated Results”. For Canada, this measure is presented in functional currency and the table below reconciles, for road transportation fuel, Revenues and Cost of sales, excluding depreciation, amortization and impairment, as per IFRS Accounting Standards, to Gross profit and the resulting road transportation fuel gross margin. This measure is considered useful for evaluating how efficiently we generate gross profit by gallon or liter of road transportation fuel sold.

Normalized growth of operating, selling, general and administrative expenses (“normalized growth of expenses”). Normalized growth of expenses consists of the growth of Operating, selling, general and administrative expenses adjusted for the impact of the changes in our network, the impact from changes in accounting policies and adoption of accounting standards, the impact of more volatile items over which we have limited control including, but not limited to, the net impact of foreign exchange translation, electronic payment fees excluding acquisitions, acquisition costs, and incremental system integration costs related to acquisitions, as well as other specific items for which the impact on consolidated results is not deemed indicative of future trends. Please note that the composition of this measure was adjusted to include the incremental system integration costs related to acquisitions, given the level of associated efforts is related to the magnitude and complexity of the acquired businesses. This measure is considered useful for evaluating our ability to control our expenses on a comparable basis.

The tables below reconcile growth of Operating, selling, general and administrative expenses to normalized growth of  expenses:

Growth of (decrease in) same-store merchandise revenues for Europe and other regions. Same-store merchandise revenues represent cumulative merchandise revenues between the current period and comparative period for those stores that were open for at least 23 days out of every 28-day period included in the reported periods. Merchandise revenues are defined as Merchandise and service revenues excluding service revenues. For Europe and other regions, the growth of (decrease in) same-store merchandise revenues is calculated based on constant currencies using the respective current period average exchange rate for both the current and corresponding period. In Europe and other regions, same-store merchandise revenues include same-store revenues from company-operated stores, as well as CODO and DODO stores which are not included in our consolidated results. This measure is considered useful for evaluating our ability to generate organic growth on a comparable basis in our overall European and other regions store network. Growth of (decrease in) same-store merchandise revenues for Europe and other regions include results from the acquisition of certain European retail assets from TotalEnergies SE starting December 28, 2023. 

The tables below reconcile Merchandise and service revenues, as per IFRS Accounting Standards, to same-store merchandise revenues for Europe and other regions and the resulting percentage of growth (decrease):

Earnings before interest, taxes, depreciation, amortization and impairment (“EBITDA”) and adjusted EBITDA. EBITDA represents Net earnings plus Income taxes, Net financial expenses, and Depreciation, amortization and impairment. Adjusted EBITDA represents the EBITDA adjusted for acquisition costs, the impact from changes in accounting policies and adoption of accounting standards, as well as other specific items for which the impact on consolidated results is not deemed indicative of future trends. These performance measures are considered useful to facilitate the evaluation of our ongoing operations and our ability to generate cash flows to fund our cash requirements, including our capital expenditures program, share repurchases, and payment of dividends.

The table below reconciles Net earnings, as per IFRS Accounting Standards, to EBITDA and adjusted EBITDA:

Adjusted net earnings attributable to shareholders of the Corporation and adjusted diluted net earnings per share. Adjusted net earnings attributable to shareholders of the Corporation represents Net earnings attributable to shareholders of the Corporation adjusted for net foreign exchange gains or losses, acquisition costs, the impact from changes in accounting policies and adoption of accounting standards, impairment on goodwill, investments in subsidiaries, joint ventures and associated companies, as well as other specific items for which the impact on consolidated results is not deemed indicative of future trends, and the impact of the non-controlling interests on the items mentioned previously. These measures are considered useful for evaluating the underlying performance of our operations on a comparable basis.

The table below reconciles Net earnings attributable to shareholders of the Corporation, as per IFRS Accounting Standards, with adjusted net earnings attributable to shareholders of the Corporation and adjusted diluted net earnings per share:

Interest-bearing debt. This measure represents the sum of the following balance sheet accounts: Short-term debt and current portion of long-term debt, Long-term debt, Current portion of lease liabilities and Lease liabilities. This measure is considered useful to facilitate the understanding of our financial position in relation with financing obligations. The calculation of this measure of financial position is detailed in the “Net interest-bearing debt/total capitalization” section below.

Net interest-bearing debt/total capitalization. This measure represents the basis for monitoring our capital and is considered useful to assess our financial health, risk profile, and ability to meet our financing obligations. It also provides insights into how our financing obligations are structured in relation with our total capitalization. 

The table below presents the calculation of this performance measure:

Leverage ratio. This measure represents a measure of financial condition considered useful to assess our financial leverage and our ability to cover our net financing obligations in relation to our adjusted EBITDA.

The table below reconciles net interest-bearing debt and adjusted EBITDA, for which the calculation methodologies are described in other tables of this section, with the leverage ratio:

Return on equity. This measure is considered useful to assess the relationship between our profitability and our net assets and it also provides insights into how efficiently we are using our equity to generate returns for our shareholders. Average equity attributable to shareholders of the Corporation is calculated by taking the average of the opening and closing balance for the 52-week periods.

The table below reconciles Net earnings attributable to shareholders of the Corporation, as per IFRS Accounting Standards, with the ratio of return on equity:

Return on capital employed. This measure is considered useful as it provides insights into our ability to generate returns from the total amount of capital invested in our operations and it also helps in assessing our operational efficiency and capital allocation decisions. Earnings before interest and taxes (“EBIT”) represents Net earnings plus Income taxes and Net financial expenses. Capital employed represents total assets less short-term liabilities not bearing interest, which excludes the Short-term debt and current portion of long-term debt and Current portion of lease liabilities. Average capital employed is calculated by taking the average of i) the opening balance of capital employed for the 52-week periods and ii) the ending balance of capital employed for the 52-week periods.

The table below reconciles Net earnings, as per IFRS Accounting Standards, to EBIT with the ratio of Return on capital employed:

Profile

Couche-Tard is a global leader in convenience and mobility, operating in 29 countries and territories, with close to 17,300 stores, of which approximately 13,200 offer road transportation fuel. With its well-known Couche-Tard and Circle K banners, it is one of the largest independent convenience store operators in the United States and it is a leader in the convenience store industry and road transportation fuel retail in Canada, Scandinavia, the Baltics, Belgium, as well as in Ireland. It also has an important presence in Luxembourg, Germany, the Netherlands, Poland, as well as in Hong Kong Special Administrative Region of the People’s Republic of China. Approximately 149,500 people are employed throughout its network.

For more information on Alimentation Couche-Tard Inc., or to consult its audited annual Consolidated Financial Statements, unaudited interim condensed consolidated financial statements and Management Discussion and Analysis or other filings made with Canadian securities regulatory authorities, please visit: https://corpo.couche-tard.com or SEDAR+ under Couche-Tard’s profile at www.sedarplus.ca.

Webcast on November 25, 2025 at 8:00 A.M. (EST)

Couche-Tard invites analysts known to the Corporation to ask their questions to its management on November 25, 2025, during the question and answer period of the webcast.

Financial analysts, investors, media, and other interested parties are invited to join the webcast on November 25, 2025, at 8:00 A.M. (EST). A presentation will include slides detailing the quarterly and fiscal year results. The webcast can be accessed via the “Investors/Events & Presentations” section on the Corporation’s website https://corpo.couche-tard.com/ or directly via this link https://emportal.ink/3HqoQrB to join the call without operator assistance.

Another option could be to access the conference call through an operator by dialing 1-289-819-1299 or the international number 1-800-990-4777.

Rebroadcast: For individuals who will not be able to listen to the live webcast, a recording of the webcast will be available on the Corporation’s website for a period of 90 days.

2026 Business Strategy Update

Couche-Tard also announces today that it will host its 2026 Business Strategy Update on February 11, 2026 in Toronto, ON. The event will include presentations and Q&A from selected members of the executive team outlining the next phase growth and key priorities. Additional details, including registration information, will be shared closer to the date.

Forward-looking statements

The statements set forth in this press release, which describes Couche-Tard’s objectives, projections, estimates, expectations, or forecasts, may constitute forward-looking statements within the meaning of securities legislation. Positive or negative verbs such as “believe”, “can”, “shall”, “intend”, “expect”, “estimate”, “assume”, and other related expressions are used to identify such statements. Although we base the forward-looking statements contained in this press release on assumptions that we believe are reasonable, by their very nature, forward-looking statements involve risks and uncertainties such that actual results (including our results of operations, financial condition and liquidity, the achievement of our targets, goals and commitments, the development of the industry in which we operate or the measures we adopt) could differ materially from those indicated in or underlying these statements, or could have an impact on the degree of realization of a particular projection or expectation. Major factors that may lead to a material difference between Couche-Tard’s actual results and the projections or expectations set forth in the forward-looking statements include the effects of the integration of acquired businesses and the ability to achieve projected synergies, ongoing military conflicts, fluctuations in margins on motor fuel sales, competition in the convenience store and retail motor fuel industries, exchange rate variations, and such other risks as described in detail from time to time in the reports filed by Couche-Tard with securities authorities in Canada available on SEDAR+ under Couche-Tard’s profile at www.sedarplus.ca, including under “Business Risks” in our management discussion and analysis for the 52-week period ended April 27, 2025. The risks described herein and therein are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also significantly impair our business, financial position or results of operations. Unless otherwise required by applicable securities laws, Couche-Tard disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking information in this release is based on information available as of the date of the release.

SOURCE Alimentation Couche-Tard Inc.

LONDON, Nov. 24, 2025 /PRNewswire/ — Brightstar Lottery PLC (NYSE: BRSL) (“Brightstar”) announced today that it has signed a contract with Pan Malaysian Pools SDN BHD (“PMP”), a licensed numbers forecast operator in Malaysia, to supply and deliver 1,200 Retailer Pro S2 terminals as part of PMP’s ongoing quest to upgrade its business infrastructure. The Retailer Pro S2 offers high performance, reliability, and a variety of options and peripherals to meet the current and future needs of lotteries and retailers.

“Deploying Brightstar’s Retailer Pro S2 terminals will provide several added benefits for PMP, our retailers, and players,” said Tan Kong Han, PMP Managing Director. “The many components of this sophisticated terminal will support PMP in our efforts to offer modern experiences for our players, reliable solutions for retailers, and enhance productivity and profitability in our business that continuously funds The Community Chest, which establishes and develops schools throughout Malaysia.”

“Brightstar’s Retailer Pro S2 represents the next-generation evolution of our industry-leading Retailer Pro terminal, now more compact, powerful, and flexible,” said Marco Tasso, Brightstar Chief Operating Officer International and Italy Operations. “Designed for dynamic retail environments like those in Malaysia, the S2 redefines player engagement by offering a range of interactive options that elevate the experience for PMP’s players.”

Engineered for speed and reliability, the Retailer Pro S2 features a 15.6″ full HD clerk-facing touchscreen and is powered by a high-performance processor that ensures rapid transaction processing. Its ergonomic, modular design supports multiple player-facing displays and a broad range of peripherals – including barcode scanners, fingerprint readers, NFC technology, and webcams – enabling flexible and engaging player interactions. This next-generation terminal reflects Brightstar’s commitment to innovation and operational excellence across diverse retail environments.

Brightstar serves nearly 90 lottery customers and their players on six continents. It is the primary technology provider to 26 of the 46 lottery jurisdictions in the U.S. and eight of the world’s 10 largest lotteries.

For more information, visit us at brightstarlottery.com or follow along on LinkedIn.

About Brightstar Lottery PLC
Brightstar Lottery PLC (NYSE: BRSL) is an innovative, forward-thinking global leader in lottery that builds on our renowned expertise in delivering secure technology and producing reliable, comprehensive solutions for our customers. As a premier pure play global lottery company, our best-in-class lottery operations, retail and digital solutions, and award-winning lottery games enable our customers to achieve their goals, entertain players and distribute meaningful benefits to communities. Brightstar has a well-established local presence and is a trusted partner to governments and regulators around the world, creating value by adhering to the highest standards of service, integrity, and responsibility. Brightstar has approximately 6,000 employees. For more information, please visit www.brightstarlottery.com.

Cautionary Statement Regarding Forward-Looking Statements
This news release may contain forward-looking statements (including within the meaning of the Private Securities Litigation Reform Act of 1995) concerning Brightstar Lottery PLC and its consolidated subsidiaries (the “Company”) and other matters. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, products and services, customer relationships, results of operations, or financial condition, or otherwise, based on current beliefs of the management of the Company as well as assumptions made by, and information currently available to, such management. Forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “plan,” “could,” “would,” “should,” “shall,” “continue,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project” or the negative or other variations of them. These forward-looking statements speak only as of the date on which such statements are made and are subject to various risks and uncertainties, many of which are outside the Company’s control. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may differ materially from those predicted in the forward-looking statements and from past results, performance, or achievements. Therefore, you should not place undue reliance on such statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include (but are not limited to) macroeconomic, regulatory and political uncertainty, including as a result of new or increased tariffs, trade wars, and other restrictions on trade between or among countries in which the Company operates, and related changes in discretionary consumer spending and behavior, fluctuations in foreign currency exchange rates, and the other factors and risks described in the Company’s annual report on Form 20-F for the financial year ended December 31, 2024 and other documents filed or furnished from time to time with the SEC, which are available on the SEC’s website at www.sec.gov and on the investor relations section of the Company’s website at www.brightstarlottery.com. Except as required under applicable law, the Company does not assume any obligation to update these forward-looking statements. You should carefully consider these factors and other risks and uncertainties that may affect the Company’s business. All forward-looking statements contained in this news release are qualified in their entirety by this cautionary statement. All subsequent written or oral forward-looking statements attributable to the Company, or persons acting on its behalf, are expressly qualified in their entirety by this cautionary statement.

Contact:
Mike DeAngelis, Corporate Communications, +1 (401) 392-1000, [email protected]
Matteo Selva, Italian media inquiries, +39 366 6803635
James Hurley, Investor Relations, +1 (401) 392-7190

© 2025 Brightstar Lottery PLC

The trademarks and/or service marks used herein are either trademarks or registered trademarks of Brightstar Lottery PLC, its affiliates or its licensors.

SOURCE Brightstar Lottery PLC

THOUSAND OAKS, Calif., Nov. 24, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at Citi’s 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen‘s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. 

In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. 

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, YouTube and Threads.

CONTACT: Amgen, Thousand OaksElissa Snook, 609-251-1407 (media) Casey Capparelli, 805-447-1746 (investors)  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2025-global-healthcare-conference-302623658.html

SOURCE Amgen